Quantisnow Logo
Dashboard

Boston Scientific Announces Participation in the J.P. Morgan Healthcare Conference and Conference Call Discussing Fourth Quarter 2024 Results

$BSX
Medical/Dental Instruments
Health Care
Get the next $BSX alert in real time by email

MARLBOROUGH, Mass., Jan. 2, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) will participate in the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, in San Francisco. Mike Mahoney, chairman and chief executive officer, will present at approximately 5:15 p.m. PT / 8:15 p.m. ET. Mahoney will be joined by Dan Brennan, executive vice president and chief financial officer, and Kenneth Stein, M.D., senior vice president and chief medical officer, in a question-and-answer session with the host analyst.

Additionally, the company will webcast its conference call discussing financial results and business highlights for the fourth quarter ended December 31, 2024, on Wednesday, February 5, 2025, at 8:00 a.m. ET. The call will be hosted by Mike Mahoney and Dan Brennan. The company will issue a news release announcing financial results for the fourth quarter on February 5 prior to the conference call.

A live webcast and replay for each event will be accessible at htts://investors.bostonscientific.com. The replays will be available approximately one hour following the completion of each event.

About Boston Scientific

Boston Scientific transforms lives through innovative medical technologies that improve the health of patients around the world. As a global medical technology leader for more than 45 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of health care. Our portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions. Learn more at www.bostonscientific.com and connect on LinkedIn and X, formerly Twitter.  

CONTACTS:

Chanel Hastings

Media Relations

+1 (508) 382-0288

Chanel.Hastings@bsci.com

Jon Monson

Investor Relations

+1 (508) 683-5450

BSXInvestorRelations@bsci.com 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/boston-scientific-announces-participation-in-the-jp-morgan-healthcare-conference-and-conference-call-discussing-fourth-quarter-2024-results-302340448.html

SOURCE Boston Scientific Corporation

Get the next $BSX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$BSX

DatePrice TargetRatingAnalyst
4/16/2025$113.00Hold → Buy
Needham
1/10/2025$108.00Hold → Buy
Deutsche Bank
10/18/2024Buy → Hold
Needham
5/30/2024$90.00Buy
Goldman
2/1/2024$65.00 → $80.00Neutral → Buy
Mizuho
7/19/2023$59.00Outperform
Robert W. Baird
6/30/2023$64.00Buy
CL King
5/30/2023$58.00Overweight
Morgan Stanley
More analyst ratings

$BSX
 Press Releases

Fastest customizable press release news feed in the world

See more

  • Boston Scientific Chief Financial Officer (CFO) Dan Brennan to retire; Jon Monson, senior vice president, Investor Relations to succeed Brennan

    MARLBOROUGH, Mass., April 23, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) today announced that Dan Brennan, executive vice president and chief financial officer, has elected to retire following nearly 30 successful years with the company. Brennan will transition out of the chief financial officer position at the end of June and is expected to remain with Boston Scientific as a senior advisor through early October 2025.   "I thank Dan for his incredible leadership and tremendous contributions to Boston Scientific," said Mike Mahoney, chairman and chief executi

    $BSX
    Medical/Dental Instruments
    Health Care

  • Boston Scientific announces results for first quarter 2025

    MARLBOROUGH, Mass., April 23, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) generated net sales of $4.663 billion during the first quarter of 2025, growing 20.9 percent on a reported basis, 22.2 percent on an operational1 basis and 18.2 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $674 million or $0.45 per share (EPS), compared to $495 million or $0.33 per share a year ago, and achieved adjusted3 EPS of $0.75 for the period, compared to $0.56 a year ago.

    $BSX
    Medical/Dental Instruments
    Health Care

  • Nalu Medical Appoints Veteran Medtech Executive Raymond W. Cohen Chairman of its Board of Directors

    Nalu Medical, Inc. ("Nalu") announced today the appointment of Raymond W. Cohen to serve as chairman of its board of directors. Raymond Cohen served as the chief executive officer and member of the board of directors of Nasdaq-listed Axonics, Inc., a medical device company he co-founded in 2013 and took public in late October 2018. Axonics ranked No. 1 on the Deloitte Technology Fast 500™ and the Financial Times ranking of the fastest growing companies in the Americas in 2021 and 2022. Cohen retired from Axonics following the November 2024 close of its $3.7 billion sale to Boston Scientific Corporation (NYSE:BSX). Following the sale of Axonics, Cohen was named chairman of the board of Son

    $BSX
    $KMTS
    Medical/Dental Instruments
    Health Care

$BSX
 Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$BSX
 Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$BSX
 Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$BSX
 SEC Filings

See more

$BSX
 FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

See more

  • March 1, 2024 - FDA Roundup: March 1, 2024

    For Immediate Release: March 01, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA issued a letter of enforcement discretion for certain qualified health claims regarding the consumption of yogurt and the reduced risk of type 2 diabetes. The letter states that the FDA does not intend to object to the use of these claims, provide

    $BSX
    Medical/Dental Instruments
    Health Care

$BSX
 Leadership Updates

Live Leadership Updates

See more

  • Nalu Medical Appoints Veteran Medtech Executive Raymond W. Cohen Chairman of its Board of Directors

    Nalu Medical, Inc. ("Nalu") announced today the appointment of Raymond W. Cohen to serve as chairman of its board of directors. Raymond Cohen served as the chief executive officer and member of the board of directors of Nasdaq-listed Axonics, Inc., a medical device company he co-founded in 2013 and took public in late October 2018. Axonics ranked No. 1 on the Deloitte Technology Fast 500™ and the Financial Times ranking of the fastest growing companies in the Americas in 2021 and 2022. Cohen retired from Axonics following the November 2024 close of its $3.7 billion sale to Boston Scientific Corporation (NYSE:BSX). Following the sale of Axonics, Cohen was named chairman of the board of Son

    $BSX
    $KMTS
    Medical/Dental Instruments
    Health Care

  • Sherpa Healthcare Partners Appoints Veteran MedTech Executive Raymond W. Cohen as Venture Partner

    BEIJING and IRVINE, Calif., Jan. 6, 2025 /PRNewswire/ -- Sherpa Healthcare Partners, a global healthcare venture capital firm focused on early and growth stage healthcare companies primarily in Asia and the United States, announced today the appointment of Raymond W. Cohen as Venture Partner. Mr. Cohen is a seasoned healthcare executive and until recently, served as the CEO and member of the board of directors of Axonics, Inc., an Irvine, California-based global medical technology company that Cohen co-founded in 2013 and took public in late October 2018. Axonics ranked No. 1

    $BSX
    Medical/Dental Instruments
    Health Care

  • SoniVie Ltd., Appoints Veteran Medtech Executive Raymond W. Cohen as Chairman of its Board of Directors

    TEL AVIV, Israel, Nov. 14, 2024 /PRNewswire/ -- SoniVie Ltd., a medical device company developing a proprietary renal denervation system to treat hypertension, announced today the appointment of Raymond W. Cohen to serve as its chairman of the board of directors. Mr. Cohen has served as the chief executive officer and member of the board of directors of Axonics, Inc., an Irvine, Calif. based global medical technology company he cofounded in 2013 and took public October 31, 2018. Axonics ranked No. 1 on the 2021 Deloitte Technology Fast 500™ and the 2022 Financial Times ranking of the fastest growing companies in the Americas. Cohen is retiring from Axonics following the close of its $3.7 bi

    $BSX
    Medical/Dental Instruments
    Health Care

$BSX
 Financials

Live finance-specific insights

See more

  • Boston Scientific announces results for first quarter 2025

    MARLBOROUGH, Mass., April 23, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) generated net sales of $4.663 billion during the first quarter of 2025, growing 20.9 percent on a reported basis, 22.2 percent on an operational1 basis and 18.2 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $674 million or $0.45 per share (EPS), compared to $495 million or $0.33 per share a year ago, and achieved adjusted3 EPS of $0.75 for the period, compared to $0.56 a year ago.

    $BSX
    Medical/Dental Instruments
    Health Care

  • Boston Scientific announces conference call discussing first quarter 2025 results

    MARLBOROUGH, Mass., April 1, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the first quarter ended March 31, 2025, on Wednesday, April 23, 2025, at 8:00 a.m. ET. The call will be hosted by Mike Mahoney, chairman and chief executive officer, and Dan Brennan, executive vice president and chief financial officer. The company will issue a news release announcing financial results for the first quarter on April 23 prior to the conference call. A live webcast and replay for the

    $BSX
    Medical/Dental Instruments
    Health Care

  • Boston Scientific announces results for fourth quarter and full year 2024

    MARLBOROUGH, Mass., Feb. 5, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) generated net sales of $4.561 billion during the fourth quarter of 2024, growing 22.4 percent on a reported basis, 23.1 percent on an operational1 basis and 19.5 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $566 million or $0.38 per share (EPS), compared to $504 million or $0.34 per share a year ago and achieved adjusted3 EPS of $0.70 for the period, compared to $0.55 a year ago.

    $BSX
    Medical/Dental Instruments
    Health Care

$BSX
 Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more